Medicinal chemistry approaches for the treatment and prevention of Alzheimer disease

被引:85
作者
Bachurin, SO [1 ]
机构
[1] Russian Acad Sci, Inst Physiol Act Cpds, Chernogolovka 142432, Moscow Region, Russia
关键词
Alzheimer's disease; beta-amyloid; cognition enhancers; neuroprotectors;
D O I
10.1002/med.10026
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease (AD) is the most common form of dementia, which is characterised by progressive deterioration of memory and higher cortical functions that ultimately result in total degradation of intellectual and mental activities. Modern strategies in the search of new therapeutic approaches are based on the morphological and biochemical characteristics of AD, and focused on following directions: agents that compensate the hypofunction of cholinergic system, agents that interfere with the metabolism of beta-amyloid peptide, agents that protect nerve cells from toxic metabolites formed in neurodegenerative processes, agents that activate other neurotransmitter systems that indirectly compensate for the deficit of cholinergic functions, agents that affect the process of the formation of neurofibrillary tangles, anti-inflammatory agents that prevent the negative response of nerve cells to the pathological process. The goal of the present review is the validation and an analysis from the point of view of medicinal chemistry of the principles of the directed search of drugs for the treatment and prevention of AD and related neurodegenerative disorders. It is based on systematization of the data on biochemical and structural similarities in the interaction between physiologically active compounds and their biological targets related to the development of such pathologies. The main emphasis is on cholinomimetic, anti-amyloid and anti-metabolic agents, using the data that were published during the last 3 to 4 years, as well as the results of clinical trials presented on corresponding websites. (C) 2002 Wiley Periodicals, Inc.
引用
收藏
页码:48 / 88
页数:41
相关论文
共 217 条
[1]  
Abe K, 1996, J NEUROCHEM, V67, P2074
[2]   A randomized controlled trial of prednisone in Alzheimer's disease [J].
Aisen, PS ;
Davis, KL ;
Berg, JD ;
Schafer, K ;
Campbell, K ;
Thomas, RG ;
Weiner, MF ;
Farlow, MR ;
Sano, M ;
Grundman, M ;
Thal, LJ .
NEUROLOGY, 2000, 54 (03) :588-593
[3]   Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease [J].
Aisen, PS ;
Marin, DB ;
Brickman, AM ;
Santoro, J ;
Fusco, M .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2001, 15 (02) :96-101
[4]  
Aisen PS, 1997, INT J GERIATR PSYCHO, V1, P2
[5]   Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on glutamate cytotoxicity in cultured cortical neurons [J].
Akaike, A ;
Maeda, T ;
Kaneko, S ;
Tamura, Y .
JAPANESE JOURNAL OF PHARMACOLOGY, 1998, 76 (02) :219-222
[6]   Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[7]   Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease [J].
Allison, AC ;
Cacabelos, R ;
Lombardi, VRM ;
Alvarez, XA ;
Vigo, C .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2001, 25 (07) :1341-1357
[8]  
Alvarez XA, 1999, METHOD FIND EXP CLIN, V21, P633
[9]  
Alvarez XA, 2000, METHOD FIND EXP CLIN, V22, P585
[10]   On the antioxidant activity of melatonin [J].
Antunes, F ;
Barclay, LRC ;
Ingold, KU ;
King, M ;
Norris, JQ ;
Scaiano, JC ;
Xi, FD .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (1-2) :117-128